KR101493543B1 - 4-아미노퀴놀린-3-카르보니트릴을 이용한 이마티닙 내성 백혈병의 치료 - Google Patents

4-아미노퀴놀린-3-카르보니트릴을 이용한 이마티닙 내성 백혈병의 치료 Download PDF

Info

Publication number
KR101493543B1
KR101493543B1 KR1020097027540A KR20097027540A KR101493543B1 KR 101493543 B1 KR101493543 B1 KR 101493543B1 KR 1020097027540 A KR1020097027540 A KR 1020097027540A KR 20097027540 A KR20097027540 A KR 20097027540A KR 101493543 B1 KR101493543 B1 KR 101493543B1
Authority
KR
South Korea
Prior art keywords
leukemia
compound
delete delete
imatinib
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097027540A
Other languages
English (en)
Korean (ko)
Other versions
KR20100017983A (ko
Inventor
베커 휴즈
Original Assignee
와이어쓰 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101493543(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 와이어쓰 엘엘씨 filed Critical 와이어쓰 엘엘씨
Publication of KR20100017983A publication Critical patent/KR20100017983A/ko
Application granted granted Critical
Publication of KR101493543B1 publication Critical patent/KR101493543B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020097027540A 2007-06-01 2008-05-30 4-아미노퀴놀린-3-카르보니트릴을 이용한 이마티닙 내성 백혈병의 치료 Active KR101493543B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01
US60/932,650 2007-06-01
PCT/US2008/065215 WO2008150957A2 (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Publications (2)

Publication Number Publication Date
KR20100017983A KR20100017983A (ko) 2010-02-16
KR101493543B1 true KR101493543B1 (ko) 2015-02-13

Family

ID=39639071

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097027540A Active KR101493543B1 (ko) 2007-06-01 2008-05-30 4-아미노퀴놀린-3-카르보니트릴을 이용한 이마티닙 내성 백혈병의 치료

Country Status (23)

Country Link
US (1) US11103497B2 (https=)
EP (4) EP2152267A2 (https=)
JP (3) JP5888853B2 (https=)
KR (1) KR101493543B1 (https=)
CN (1) CN101686973B (https=)
AU (1) AU2008260070B9 (https=)
BR (1) BRPI0812355A2 (https=)
CA (3) CA2964162C (https=)
CL (1) CL2008001577A1 (https=)
CY (2) CY1115251T1 (https=)
DK (2) DK2478905T3 (https=)
ES (2) ES2881391T3 (https=)
HU (1) HUE055524T2 (https=)
IL (1) IL202407A0 (https=)
MX (1) MX2009013069A (https=)
PA (1) PA8782301A1 (https=)
PL (2) PL2478905T3 (https=)
PT (2) PT2478905E (https=)
RU (1) RU2464026C2 (https=)
SI (2) SI2478905T1 (https=)
TW (1) TW200908982A (https=)
WO (1) WO2008150957A2 (https=)
ZA (1) ZA200908480B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2964162C (en) 2007-06-01 2019-12-31 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
SG192769A1 (en) 2011-03-04 2013-09-30 Glaxosmithkline Ip No 2 Ltd Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
RU2662810C2 (ru) 2013-02-21 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Хиназолины в качестве ингибиторов киназы
KR101733665B1 (ko) 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
JP2022544700A (ja) * 2019-08-22 2022-10-20 バイオヘイブン・セラピューティクス・リミテッド 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用
WO2025024311A2 (en) * 2023-07-21 2025-01-30 Icahn School Of Medicine At Mount Sinai G9a/glp inhibitors and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101780A1 (en) * 2003-11-06 2005-05-12 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
AU2002245296B2 (en) * 2001-01-25 2006-12-21 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
PT2017335E (pt) 2001-10-05 2011-03-02 Novartis Ag Domínios da cinase abl mutados
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
NL1031674C2 (nl) 2005-04-25 2007-04-26 Pfizer Antilichamen tegen myostatine.
DE602006014540D1 (en) * 2005-05-16 2010-07-08 Irm Llc Pyrrolopyridinderivate als proteinkinaseinhibitoren
EP1904654A2 (en) 2005-07-15 2008-04-02 Brystol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides
BRPI0616923A2 (pt) 2005-10-06 2011-07-05 Lilly Co Eli anticorpos monoclonais, seus usos e composição farmacêutica
EP1948820A2 (en) * 2005-11-04 2008-07-30 Bristol-Myers Squibb Pharma Company T315a and f317i mutations of bcr-abl kinase domain
CA2964162C (en) 2007-06-01 2019-12-31 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101780A1 (en) * 2003-11-06 2005-05-12 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Research, Vol.66, No.23, pp.11314-11322 (2006) *
Cancer Research, Vol.66, No.23, pp.11314-11322 (2006)*

Also Published As

Publication number Publication date
SI3002009T1 (sl) 2021-09-30
RU2009144128A (ru) 2011-07-20
RU2464026C2 (ru) 2012-10-20
PA8782301A1 (es) 2009-01-23
IL202407A0 (en) 2010-06-30
HK1142812A1 (en) 2010-12-17
EP3002009A3 (en) 2016-07-06
BRPI0812355A2 (pt) 2015-01-27
CN101686973A (zh) 2010-03-31
CA2964162C (en) 2019-12-31
CY1124391T1 (el) 2022-07-22
EP3002009A2 (en) 2016-04-06
TW200908982A (en) 2009-03-01
MX2009013069A (es) 2010-03-17
EP2152267A2 (en) 2010-02-17
DK3002009T3 (da) 2021-08-02
ES2881391T3 (es) 2021-11-29
CY1115251T1 (el) 2017-01-04
CA2688467C (en) 2015-05-12
JP2010529038A (ja) 2010-08-26
EP2777704A2 (en) 2014-09-17
AU2008260070B2 (en) 2011-08-18
KR20100017983A (ko) 2010-02-16
CA2868899C (en) 2017-06-13
EP2478905A3 (en) 2013-01-16
ES2477567T3 (es) 2014-07-17
JP2016074700A (ja) 2016-05-12
AU2008260070B9 (en) 2012-01-19
ZA200908480B (en) 2010-08-25
US11103497B2 (en) 2021-08-31
CA2688467A1 (en) 2008-12-11
EP3002009B1 (en) 2021-07-07
CA2964162A1 (en) 2008-12-11
HUE055524T2 (hu) 2021-11-29
PL2478905T3 (pl) 2014-10-31
WO2008150957A3 (en) 2009-08-06
JP5888853B2 (ja) 2016-03-22
PL3002009T3 (pl) 2021-12-13
US20080318971A1 (en) 2008-12-25
SI2478905T1 (sl) 2014-07-31
CA2868899A1 (en) 2008-12-11
EP2478905B1 (en) 2014-05-14
AU2008260070A1 (en) 2008-12-11
PT2478905E (pt) 2014-07-16
JP2014111629A (ja) 2014-06-19
CN101686973B (zh) 2013-06-19
DK2478905T3 (da) 2014-06-30
WO2008150957A2 (en) 2008-12-11
EP2777704A3 (en) 2015-01-21
CL2008001577A1 (es) 2008-07-25
PT3002009T (pt) 2021-08-02
EP2478905A2 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
KR101493543B1 (ko) 4-아미노퀴놀린-3-카르보니트릴을 이용한 이마티닙 내성 백혈병의 치료
EP0785252B1 (en) Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer
CN118785911A (zh) 用于治疗肿瘤的药物组合物
US7919625B2 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
CN119733053A (zh) Kras g12c抑制剂与米托蒽醌的药物组合及其用途
AU4851599A (en) Method for inhibiting c-jun expression using jak-3 inhibitors
CN110652514A (zh) 第三代egfr抑制剂的制药用途
CN112426424A (zh) 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途
KR20250089532A (ko) 암 치료를 위한 serd의 조합
JP7640033B2 (ja) ピリド［１，２－ａ］ピリミジノン類似体の使用
US6800649B1 (en) Method for inhibiting c-jun expression using JAK-3 inhibitors
WO2017114260A1 (zh) 色胺酮及其衍生物在制备hIDO2抑制剂中的用途
US20250161276A1 (en) Drug combinations and methods of treating ovarian cancer
HK1142812B (en) Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
WO2024088192A1 (en) An aurora a inhibitor for use in treatments of cancers

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20171228

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 6, Claim Number : 1 4, 7, 8, Period Limitation Text : 1826, Comment Text : 328, 329, 330

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 6, Claim Number : 1 4, 7, 8, Period Limitation Text : 1826, Comment Text : 328, 329, 330

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 12